`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ALEMBIC PHARMACEUTICALS, LTD.,
`
`Petitioner,
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.,
`
`Patent Owner.
`
`Case No. IPR2016—01245
`
`Patent No. RE38,55 1
`
`PATENT OWNER RESEARCH CORPORATION TECHNOLOGIES,
`INC.’S MANDATORY NOTICES UNDER 37 C.F.R. § 42.8
`
`
`
`Patent No. RE38,551
`
`Case No. IPR2016-01245
`
`Pursuant
`
`to 37 C.F.R.
`
`§ 42.8, Patent Owner Research Corporation
`
`Technologies, Inc. submits the following Mandatory Notices. In accordance with
`
`37 C.F.R. 42.8(a)(2), these Mandatory Notices are being timely filed within 21
`
`days of service of the petition.
`
`A.
`
`Real Party-In-Interest Under 37 C.F.R. § 42.8(b)(1)
`
`The real parties-in-interest are Research Corporation Technologies, Inc.;
`
`Harris FRC Corporation; UCB, Inc.; UCB Biopharma SPRL; and UCB Pharma
`
`GmbH.
`
`B.
`
`Related Matters Under 37 C.F.R. § 42.8(b)(2)
`
`The Patent Trial and Appeal Board denied an earlier filed Petition for Inter
`
`Partes Review of RE38,551, IPR2014-01126. A second Petition for Inter Partes
`
`Review of RE38,551, IPR2016—00204, was filed on November 23, 2015, and was
`
`instituted on May 23, 2016. Three further Petitions for Inter Partes Review of
`
`RE38,551 have been filed: IPR2016-01101, May 25, 2016; IPR2016-01242, June
`
`21, 2016;
`
`and IPR2016—01248,
`
`June 23, 2016. A request
`
`for
`
`ex parte
`
`reexamination of RE38,551 (Control No. 90/013,709) was filed on March 25,
`
`2016, and granted on June 16, 2016.
`
`Patent Owner further identifies the following related judicial proceedings
`
`involving RE38,551:
`
`
`
`Patent No. RE38,551
`
`Case No. IPR2016—01245
`
`Disposition
`closed
`
`J
`
`___1
`
`pending
`(_
`pending, Consolidated with
`1:13-cV—O1206—LPS (D. Del)_
`pending, consolidated with
`1:13-cV—O1206—LPS (D. Del)
`pending, consolidated with
`1:13—cV-01206-LPS (D. Del.)
`pending, consolidated with
`1:13-cV—O1206—LPS (D. Del.)
`pending, consolidated with
`1:13-CV—01206~LPS (D. Del.)
`closed
`
`Case Caption
`UCB, Inc. et al. v. Teva Pharmaceuticals USA Inc.
`[et al., 1:13-CV—O1148—LPS (D. Del.)
`UCB, Inc. et al. 12. Accord Healthcare Inc. et al.,
`(1213-CV-01206-LPS (D. Del)
`UCB, Inc. et al. v. Alembic Pharmaceuticals Ltd.,
`1:13—cV—01207—LPS (D. Del.)
`UCB, Inc. et al. v. Amneal Pharmaceuticals, LLC
`et al., 1:13—cV-01208—LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., l:13—cv-
`O1209—LPS (D. Del.)
`UCB, Inc. et al. v. Aurobindo Pharma Ltd. et al.,
`1:13-CV-0l210—LPS (D. Del.)
`UCB, Inc. et al. v. Breckenridge Pharmaceutical
`Inc. et al., 1:13—cV—01211—LPS (D. Del.)
`UCB, Inc. et al. v. Glenmark Generics Inc. USA et
`al., 1:13—cV—01212—LPS (D. Del.)
`UCB, Inc. et al. v. Hetero USA Inc. et al., 1:13—cV- Closed
`O1213—LPS (D. Del.)
`UCB, Inc. et al. v. Mylan Pharmaceuticals Inc. et
`al., 1:13-CV-01214-LPS (D. Del.)
`UCB, Inc. et al. v. Ranbaxy Laboratories Ltd. et
`(al., 1:13-CV-0l2l5~LPS (D. Del.)
`UCB, Inc. et al. v. Sandoz Inc., 1:13-CV-01216—
`LPS (D. Del.)
`UCB, Inc. et al. v ScieGen Pharmaceuticals Inc. et Closed
`al., 1:13—cv-01217-LPS (D. Del)
`UCB, Inc. et al. v Sun Pharma Global FZE et al.,
`1:13-cV—01218—LPS (D. Del.)
`UCB, Inc. et al. v. Watson Laboratories Inc. —
`Florida et al., 1:13-cv—01219—LPS (D. Del_.)
`UCB, Inc. et al. v. Zydus Pharmaceuticals (USA)
`Inc. et al., 1:13—cV—Ol220—LPS
`Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:l4—CV—
`00834-LPS (D. Del.)
`
`L
`
`pending, Consolidated with
`1:13—cv~01206—LPS (D. Del.)
`closed
`
`Closed
`
`pending, consolidated with
`1:13~cV—01206-LPS (D. Del.)
`pending, consolidated with
`1:13-cV—O1206—LPS (D. DeL)
`pending, consolidated with
`1:13-cV—O1206—LPS (D. Del)_
`l pending, consolidated with
`1:13—cv-01206—LPS (D. Del.)
`
`
`
`Patent No. RE38,551
`
`Case No. IPR2016—01245
`
`} Case Caption
`i UCB, Inc. et al. v. Sun Plzarma Global FZE et al.,
`
`
`1:13—cv-05514 QLD. HQ
`UCB, Inc. et al., v. Zydus Pharmaceuticals (USA),
`Inc. et al., 3:13—Cv—04021 (D.N.J.)
`
`
`
`
`Disposition
`closed
`
`closed
`
`*1
`
`C.
`
`Lead and Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3)
`
`_-1
`Back-Up Counsel
`Lead Counsel
`Jennifer L. Robbins (Reg. No. 61,163)
`Andrea G. Reister (Reg NO 36 253)
`jmbbinS@COV'COm
`areister@cov.com
`.
`-
`’
`Postal and Hand-Delivery Address:
`Postal and Hand_De1iVer Address
`Covington & Burling LLP
`
`..
`'
`The New York Times Building
`Covington & Burhng LLP
`One CityCenter, 850 Tenth Street, NW 620 E hth Avenue
`Washington, DC 20001
`New Ygmk, NY 10018
`::::a:::::i,;%,2%>7:z%;2::1
`am
`L
`Facsimile: (212) 841-1010
`
`j
`
`Additional Back-Up Counsel
`Enrique D. Longton (Reg. No. 47,304)
`r1ongton@cov.com
`Postal and Hand—Delivery Address:
`Covington & Burling LLP
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`Telephone: (202) 662-5108
`Facsimile: (202) 778-5108
`
`D.
`
`Service Information Under 37 C.F.R. § 42.8(b) (4)
`
`Service information for lead and back—up counsel
`
`is provided in the
`
`designation of lead and back—up counsel, above. Service of any documents via
`
`hand-delivery may be made at the postal mailing address of the respective lead and
`
`
`
`Patent No. RE38,551
`
`Case No. IPR2016—01245
`
`back—up
`
`counsel designated above.
`
`Patent Owner Reseach Corporation
`
`Technologies, Inc. consents to electronic service by email at the above listed email
`
`addresses of lead and back—up counsel.
`
`E.
`
`Power of Attorney
`
`The aboVe—designated counsel at Covington & Burling LLP are currently
`
`counsel of record for RE38,551, thus no additional Power of Attorney is submitted
`
`herewith.
`
`Date: July 12, 2016
`
`Respectfully submitted,
`
`
` By/ ‘J
`
`Andrea G. Reisgéi
`Registration No. 36,253
`Jennifer L. Robbins
`
`Registration No. 61,163
`COVINGTON & BURLING LLP
`
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`(202) 662-6000
`Attorneys for Patent Owner
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 12th day of July 2016,
`
`the foregoing Patent Owner Research Corporation Technologies, Inc.’s Mandatory
`
`Notices Under 37 C.F.R. § 42.8 was served by FedEx®, a means at least as fast and
`
`reliable as Priority Mail Express®, on the following counsel of record for
`
`petitioner.
`
`Gary J. Speier (gspeier@carlsoncaspers.com)
`Jeffer Ali (jali@carlsoncaspers.com)
`Carlson, Caspers, Vandenburgh, Lindquist and Schuman
`225 South Sixth Street, Suite 4200
`
`Minneapolis, MN 55402
`
` Date: July 12, 2016
`Andrea G. Rei]
`r, Esq.
`
`
`Registration No.2 36,25